Kairos Pharma Announces Interim Safety Data From Phase I Trial Of Carotuximab In Combination With AstraZeneca's Osimertinib To Resensitize Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer Who Became Resistant To Osimertinib

Loading news article.

Kairos Pharma Announces Interim Safety Data From Phase I Trial Of Carotuximab In Combination With AstraZeneca's Osimertinib To Resensitize Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer Who Became Resistant To Osimertinib | WAPE

Kairos Pharma Announces Interim Safety Data From Phase I Trial Of Carotuximab In Combination With AstraZeneca's Osimertinib To Resensitize Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer Who Became Resistant To Osimertinib

Article summary

Related companies

Comments —